Inhibitors of TGFβ and receptors have entered clinical trials (45–48). CAR-T cells expressing a dominant-negative TGF-βRII enhance T-cell expansion and prostate cancer eradication in clinical trials (49). This evidence concerns the gene TGFB1 and prostate cancer.